Urate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study
Table 1
Demographic and clinical data ( = 5,948).
Age (mean ± SD)
Gender
(%)
Male
4 318 (73%)
Female
1 561 (26%)
No data available
69 (1%)
Gout flares/year (mean ± SD)
Number of patients with
(%)
Primary gout
4 008 (67%)
Secondary gout
1 278 (21%)
No data available
662 (11%)
Number of patients with
(%)
Gout in the big toe joint
4 138 (70%)
Tophi
540 (9%)
Joint damage/changes*
1 077 (18%)
Number1 of patients with concomitant disease
(%)
With at least one
4489 (75.5%)
Hypertension
4102 (69%)
Hyperlipidemia
2557 (43%)
Diabetes mellitus
1902 (32%)
Impaired renal function
976 (16.4%)
Thyroid dysfunction
431 (7.3%)
Depressions
418 (7%)
History of kidney stones
195 (3.3%)
Other
854 (14.4%)
Percentual reference to number of total collective . Assessment by the treating physician which covers clinical and probably radiographic findings. Multiple entries per patient possible.
